OTCMKTS:RHHBY

Roche Stock Forecast, Price & News

$41.70

+0.50 (+1.21 %)

(As of 05/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$41.25

▼

$41.93

50-Day Range

$40.25

▼

$43.19

52-Week Range

$39.72

▼

$47.15

Volume843,738 shs

Average Volume1.88 million shs

Market Capitalization$285.58 billion

P/E Ratio16.42

Dividend Yield1.87%

Beta0.35

30 days | 90 days | 365 days | Advanced Chart

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter.

About Roche

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Capital Calls: Roche CEO’s vaccine candour may backfire - Reuters
May 13, 2021 | reuters.com

Roche Holding AG Stock Is Believed To Be Fairly Valued - Yahoo Finance
May 13, 2021 | finance.yahoo.com

Prothena Corp. (PRTA) Secures $60M Milestone from Roche for First Patient Dosing in Phase 2b Study of Prasinezumab in Early Parkinson's Disease - StreetInsider.com
May 11, 2021 | streetinsider.com

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer - Yahoo Finance
May 11, 2021 | finance.yahoo.com

Draft Wire calls EDGE Quincy Roche steal of the Steelers draft - Steelers Wire
May 8, 2021 | steelerswire.usatoday.com

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer - Yahoo Finance
May 5, 2021 | finance.yahoo.com

The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
May 1, 2021 | seekingalpha.com

Could former Miami DE Quincy Roche revitalize the Texans' edge defense? - Texans Wire
April 26, 2021 | texanswire.usatoday.com

Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion - Yahoo Finance
April 23, 2021 | finance.yahoo.com

Roche gets FDA approval for cancer-treatment test - MarketWatch
April 23, 2021 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:RHHBY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.roche.com

Phone41-61-688-1111

Employees101,465

Year Founded1896

Sales & Book Value

Annual Sales$61.87 billion

Price / Sales4.62

Cash Flow$3.03 per share

Price / Cash Flow13.77

Book Value$5.27 per share

Price / Book7.91

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity Ratio0.36

Current Ratio1.23

Quick Ratio0.93

Price-To-Earnings

Trailing P/E Ratio16.42

Forward P/E Ratio15.62

P/E Growth3.69

Miscellaneous

Outstanding Shares6,848,490,000

Market Cap$285.58 billion

Next Earnings DateN/A

OptionableNot Optionable

Social Links

MarketRank^™

Overall MarketRank^™

1.36 out of 5 stars

Medical Sector

772nd out of 2,042 stocks

Pharmaceutical Preparations Industry

359th out of 770 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Roche.

2.4 Community Rank

Outperform Votes
Roche has received 312 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Roche has received 338 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Roche has received 52.00% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Roche and other stocks. Vote “Outperform” if you believe RHHBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RHHBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Roche pays a meaningful dividend of 1.87%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Roche does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Roche is 30.31%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Roche will have a dividend payout ratio of 27.21% next year. This indicates that Roche will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roche insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.32% of the stock of Roche is held by institutions.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Roche are expected to grow by 5.99% in the coming year, from $2.67 to $2.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Roche is 16.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.78.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roche is 16.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 41.68.
Price to Earnings Growth Ratio
Roche has a PEG Ratio of 3.69. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Roche has a P/B Ratio of 7.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Roche (OTCMKTS:RHHBY) Frequently Asked Questions

Is Roche a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roche in the last year. There are currently 2 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Roche stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RHHBY, but not buy additional shares or sell existing shares.
View analyst ratings for Roche or view top-rated stocks.

What stocks does MarketBeat like better than Roche?

Wall Street analysts have given Roche a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Roche wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Roche's stock been impacted by Coronavirus (COVID-19)?

Roche's stock was trading at $40.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RHHBY stock has increased by 1.9% and is now trading at $41.70.
View which stocks have been most impacted by COVID-19.

How often does Roche pay dividends? What is the dividend yield for Roche?

Roche declared a dividend on Friday, March 5th. Stockholders of record on Friday, March 19th will be paid a dividend of $1.2782 per share on Monday, March 29th. This represents a yield of 3.11%. The ex-dividend date of this dividend is Thursday, March 18th.
View Roche's dividend history.

Is Roche a good dividend stock?

Roche pays an annual dividend of $0.77 per share and currently has a dividend yield of 1.87%. The dividend payout ratio of Roche is 30.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Roche will have a dividend payout ratio of 27.21% next year. This indicates that Roche will be able to sustain or increase its dividend.
View Roche's dividend history.

Who are Roche's key executives?

Roche's management team includes the following people:

Dr. Severin Schwan, CEO & Exec. Director (Age 54, Pay $7.7M)
Dr. Alan Hippe, Chief Financial & Information Officer (Age 54, Pay $4.38M) (LinkedIn Profile)
Ms. Cristina A. Wilbur, Chief People Officer (Age 54, Pay $2.89M) (LinkedIn Profile)
Mr. Thomas Schinecker, Chief Exec. Officer of Roche Diagnostics (Age 46, Pay $2.8M) (LinkedIn Profile)
Mr. William N. Anderson, Chief Exec. Officer of Roche Pharmaceuticals (Age 55, Pay $6.17M) (LinkedIn Profile)
Dr. Karl Mahler, Head of Investor Relations
Ms. Claudia Boeckstiegel, Gen. Counsel (Age 57) (LinkedIn Profile)
Ms. Pascale Schmidt, Chief Compliance Officer (Age 48)
Mr. Nicolas Dunant, Head of Group Media Relations
Ehab Yousef, Head of Middle East Sub-Region 1

Who are some of Roche's key competitors?

Some companies that are related to Roche include Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), AbbVie (ABBV), Novartis (NVS), Merck & Co., Inc. (MRK), Eli Lilly and (LLY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Bayer Aktiengesellschaft (BAYRY).
View all of RHHBY's competitors.

What is Roche's stock symbol?

Roche trades on the OTCMKTS under the ticker symbol "RHHBY."

Who are Roche's major shareholders?

Roche's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.12%), Fisher Asset Management LLC (0.02%), Cullen Capital Management LLC (0.01%), Saratoga Research & Investment Management (0.01%), Kornitzer Capital Management Inc. KS (0.00%) and Osher Van de Voorde Investment Management (0.00%).

Which major investors are selling Roche stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Douglass Winthrop Advisors LLC, Riverbridge Partners LLC, LSV Asset Management, Private Capital Group LLC, Tower Bridge Advisors, Sit Investment Associates Inc., Todd Asset Management LLC, and Wendell David Associates Inc..

Which major investors are buying Roche stock?

RHHBY stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Fisher Asset Management LLC, Cullen Capital Management LLC, Saratoga Research & Investment Management, Kornitzer Capital Management Inc. KS, Associated Banc Corp, Park National Corp OH, and Pillar Pacific Capital Management LLC.

How do I buy shares of Roche?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Roche's stock price today?

One share of RHHBY stock can currently be purchased for approximately $41.70.

How much money does Roche make?

Roche has a market capitalization of $285.58 billion and generates $61.87 billion in revenue each year. The company earns $13.58 billion in net income (profit) each year or $2.54 on an earnings per share basis.

How many employees does Roche have?

Roche employs 101,465 workers across the globe.

Does Roche have any subsidiaries?

The following companies are subsidiares of Roche: 454 Life Sciences, Adheron Therapeutics, Adheron Therapeutics Inc., Anadys Pharmaceuticals, Anadys Pharmaceuticals Inc., Ariosa Diagnostics, Ariosa Diagnostics Inc., Arius Research, Ascur Versicherungsvermittlungs GmbH, BINA Technology, Bina Technologies Inc., BioImagene, BioVeris, BioVeris Corporation, Biopharm AG, Boehringer Mannheim, Borean Pharma, Chemical Manufacturing and Trading Company Limited, Chugai Pharmaceutical Co. Ltd., Disetronic Holding AG, Dutalys GmbH, F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd / Jordan P.S.C., FLLC "Roche Products Limited", FMI Germany GmbH, Flatiron Health, Flatiron Health Inc., ForSight Labs, ForSight VISION4 Inc., Foundation Medicine, Foundation Medicine Inc., Foundation Medicine Securities Corporation, Galenus Mannheim Pharma GmbH, GeneWEAVE, GeneWEAVE Biosciences Inc., Genentech, Genentech Inc., Genentech P.R. Inc., Genentech USA Inc., Genia Technologies, Hoffmann - La Roche Ltd, Hoffmann-La Roche Inc., Hoffmann-La Roche Limited, Hoffmann-La Roche Products Limited, I5 Surviving Corp., IGEN International Inc., IGEN LS LLC, IQuum, IQuum Inc., Ignyta, Ignyta Inc., Inflazome, Infogenetik Moleküler Bilgi Hizmetleri Anonim Sirketi, Institut Roche SAS, InterMune, InterMune Holdings Limited, InterMune Inc., InterMune International AG, Jecure Therapeutics Inc., Kapa Biosystems, Kapa Biosystems (Pty) Ltd, Kapa Biosystems Inc., Limited Liability Company Roche Diabetes Care Rus, Limited Liability Company Roche Diagnostics Rus, MTM Laboratories, Marcadia Biotech, Medingo Ltd., Medingo Medical Solutions, Memory Pharmaceuticals, Memory Pharmaceuticals Corp., Mirus, Museum Tinguely AG, N.V. Roche S.A., P.T. Roche Indonesia, PVT Probenverteiltechnik GmbH, Phaor AG, Piramed, Productos Roche (El Salvador) S.A. de C.V., Productos Roche (Honduras) S.A., Productos Roche (Nicaragua) S.A., Productos Roche (Panama) S.A., Productos Roche Dominicana S.R.L., Productos Roche Guatemala (Sociedad Anónima), Productos Roche Interamericana S.A. (PRISA), Productos Roche Química Farmacéutica S.A., Productos Roche S.A., Productos Roche S.A. Química e Industrial, Productos Roche S.A. de C.V., Produtos Roche Químicos e Farmacêuticos S.A., Promedior, Rabbit-Air Ltd, RoDiagnostics Egypt for Trading S.A.E, Roche (China) Holding Ltd., Roche (Hellas) S.A., Roche (Hungary) Ltd, Roche (Malaysia) Sdn. Bhd., Roche (Philippines) Inc., Roche (Shanghai) Pharmaceuticals Consulting Co. Ltd, Roche (Shanghai) Pharmaceuticals Trading Co. Ltd., Roche - Moscow Ltd., Roche AB, Roche Algérie SPA, Roche Austria GmbH, Roche Bangladesh Limited, Roche Beteiligungs GmbH, Roche Biomedical Laboratories Inc., Roche Bolivia SRL., Roche Bulgaria EOOD, Roche Cameroun SARL, Roche Capital Market Ltd, Roche Capital Services Ltd., Roche Catalyst Investments Ltd., Roche Chemische Unternehmungen AG, Roche Chile Limitada, Roche Côte d’Ivoire SARL, Roche DC Japan K. K., Roche DC México S.A. de C.V., Roche Deutschland Holding GmbH, Roche Diabetes Care (Switzerland) Ltd, Roche Diabetes Care Argentina S.A., Roche Diabetes Care Asia Pacific Pte. Ltd., Roche Diabetes Care Australia Pty Limited, Roche Diabetes Care Austria GmbH, Roche Diabetes Care Brasil Ltda., Roche Diabetes Care Deutschland GmbH, Roche Diabetes Care France SAS, Roche Diabetes Care GmbH, Roche Diabetes Care Inc., Roche Diabetes Care India Private Limited, Roche Diabetes Care Italy S.p.A., Roche Diabetes Care Limited, Roche Diabetes Care Middle East FZCO, Roche Diabetes Care Nederland B.V., Roche Diabetes Care Polska sp. z o.o., Roche Diabetes Care South Africa Proprietary Limited, Roche Diabetes Care Spain S.L., Roche Diagnostica Brasil Ltda., Roche Diagnostics (Hellas) S.A., Roche Diagnostics (Hong Kong) Limited, Roche Diagnostics (Malaysia) Sdn. Bhd., Roche Diagnostics (Shanghai) Ltd., Roche Diagnostics (Suzhou) Limited, Roche Diagnostics (Switzerland) Ltd, Roche Diagnostics (Thailand) Limited, Roche Diagnostics Asia Pacific Pte. Ltd., Roche Diagnostics Australia Pty. Limited, Roche Diagnostics Belgium NV, Roche Diagnostics Corporation, Roche Diagnostics Deutschland GmbH, Roche Diagnostics France SAS, Roche Diagnostics GmbH, Roche Diagnostics Hematology Inc., Roche Diagnostics India Private Limited, Roche Diagnostics International Ltd, Roche Diagnostics K.K., Roche Diagnostics Korea Co. Ltd., Roche Diagnostics Limited, Roche Diagnostics Ltd., Roche Diagnostics Middle East FZCO, Roche Diagnostics NZ Limited, Roche Diagnostics Nederland B.V., Roche Diagnostics Norge A/S, Roche Diagnostics Operations Inc., Roche Diagnostics Oy, Roche Diagnostics Polska Sp. z o.o., Roche Diagnostics Proprietary Limited, Roche Diagnostics S.L., Roche Diagnostics S.p.A., Roche Diagnostics Scandinavia AB, Roche Diagnostics Turkey Anonim Sirketi, Roche Diagnostics a/s, Roche Ecuador S.A., Roche Eesti OÜ, Roche Egypt LLC, Roche Egypt for Manufacturing and Trading SAE, Roche Farma (Peru) S.A., Roche Farma S.A., Roche Farmacêutica Química Lda., Roche Finance Europe B.V., Roche Finance Ltd, Roche Financial Investments Ltd., Roche Financial Management Ltd., Roche Financial Services Ltd., Roche Forum Buonas Ltd, Roche Georgia LLC, Roche Glycart, Roche Glycart Ltd, Roche Health Solutions Inc., Roche Holding (UK) Limited, Roche Holdings Inc., Roche Hong Kong Limited, Roche Innovation Center Copenhagen A/S, Roche Innovatis, Roche International Ltd., Roche International Ltd. (Montevideo Branch), Roche Intertrade Limited, Roche Ireland Limited, Roche Kazakhstan LLP, Roche Kenya Limited, Roche Korea Company Ltd., Roche Laboratories Inc., Roche Latvija SIA, Roche Lebanon S.A.R.L., Roche Long Term Foundation, Roche Makedonija DOOEL, Roche Molecular Systems Inc., Roche Myanmar Company Limited, Roche Müstahzarlari Sanayi Anonim Sirketi, Roche Nederland B.V., Roche NimbleGen, Roche Norge A/S, Roche Operations Ltd., Roche Oy, Roche PVT GmbH, Roche Pakistan Limited, Roche Palo Alto LLC, Roche Pars Co. (Ltd.), Roche Pharma (Switzerland) Ltd, Roche Pharma AG, Roche Pharmaceuticals (Israel) Ltd., Roche Pharmaceuticals Middle East FZCO, Roche Pharmholding B.V., Roche Polska Sp. z o.o., Roche Privacy GmbH, Roche Products (India) Private Limited, Roche Products (Ireland) Limited, Roche Products (Mauritius) Ltd, Roche Products (New Zealand) Limited, Roche Products (Proprietary) Limited, Roche Products Ghana Limited, Roche Products Inc., Roche Products Limited, Roche Products Ltd., Roche Products Pty. Limited, Roche Products Saudi Arabia LLC, Roche R&D Center (China) Ltd., Roche Real Estate Services Mannheim GmbH, Roche Registration GmbH, Roche Registration Limited, Roche Romania S.R.L., Roche S.A., Roche S.p.A., Roche SAS, Roche Sequencing Solutions Inc., Roche Services (Asia Pacific) Sdn. Bhd., Roche Services (Europe) Ltd, Roche Services Americas Sociedad de Responsabilidad Limitada, Roche Services Holdings Ltd., Roche Servicios S.A., Roche Servicios de México S.A. de C.V., Roche Singapore Pte. Ltd., Roche Singapore Technical Operations Pte. Ltd., Roche Sistemas de Diagnósticos Sociedade Unipessoal Lda., Roche Slovensko S.R.O., Roche TCRC Inc., Roche Thailand Limited, Roche Tunisie SA, Roche Ukraine LLC, Roche Vietnam Company Limited, Roche a/s Medicinalvarer og Kemikalier, Roche d.o.o., Roche d.o.o. farmaceutsko drustvo – Roche Ltd. Pharmaceutical Company, Roche farmacevtska družba d.o.o., Roche mtm laboratories AG, Roche s.r.o., Santaris Pharma, Sapac Corporation Ltd., Seragon Pharmaceuticals Inc., Shanghai Roche Pharmaceuticals Limited, Signature Diagnostics GmbH, Spark Therapeutics, Spring Bioscience Corp., Stratos Genomics, Syntex Corporation, Syntex Pharm AG, Syntex Pharmaceuticals International Limited, Syntex Puerto Rico Inc., Tanox Inc., Tavero AG, Tensha Therapeutics, Tensha Therapeutics Inc., Therapeutic Human Polyclonals, Therapeutic Human Polyclonals Inc., Trophos, Trophos SA, Tusk Therapeutics, Tusk Therapeutics Limited, UAB Roche Lietuva, Ventana Medical Systems, Ventana Medical Systems Inc., Verum Diagnostica GmbH, Viewics, Viewics Inc., Viewics India Private Limited, mySugr, mySugr GmbH, and mySugr Inc..

When was Roche founded?

Roche was founded in 1896.

What is Roche's official website?

The official website for Roche is www.roche.com.

Where are Roche's headquarters?

Roche is headquartered at GRENZACHERSTRASSE 124, BASEL V8, CH-4070.

How can I contact Roche?

Roche's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]

This page was last updated on 5/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here